

Francesco Pisani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10197015/publications.pdf>

Version: 2024-02-01

51
papers

2,864
citations

361413
20
h-index

189892
50
g-index

53
all docs

53
docs citations

53
times ranked

3716
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas. <i>Leukemia</i> , 2022, 36, 588-590.	7.2	23
2	Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. <i>Leukemia</i> , 2022, 36, 1870-1878.	7.2	47
3	High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3120-3131.	1.6	29
4	Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?. <i>Journal of Bone Oncology</i> , 2021, 26, 100338.	2.4	9
5	Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma. <i>Blood Advances</i> , 2020, 4, 5616-5630.	5.2	10
6	Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region. <i>Frontiers in Oncology</i> , 2020, 10, 848.	2.8	5
7	Transcriptional activation of the miR-17-92 cluster is involved in the growth-promoting effects of MYB in human Ph-positive leukemia cells. <i>Haematologica</i> , 2019, 104, 82-92.	3.5	24
8	Association between CMV and Invasive Fungal Infections After Autologous Stem Cell Transplant in Lymphoproliferative Malignancies: Opportunistic Partnership or Cause-Effect Relationship?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1373.	4.1	15
9	The Effect of Docosahexaenoic Acid and α -Lipoic Acid as Prevention of Bortezomib-Related Neurotoxicity in Patients With Multiple Myeloma. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541988858.	2.0	7
10	Role of Pregabalin in Treatment of Polyneuropathy in Multiple Myeloma Patients: A Retrospective Study. <i>Clinical Neuropharmacology</i> , 2019, 42, 167-171.	0.7	2
11	Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma. <i>Annals of Hematology</i> , 2018, 97, 1041-1048.	1.8	14
12	Lenograstim 5 μ g/kg is not superior to biosimilar filgrastim 10 μ g/kg in lymphoma patients undergoing peripheral blood stem cell mobilization after chemotherapy: preliminary results from a prospective randomized study. <i>Transfusion</i> , 2018, 58, 1143-1148.	1.6	4
13	BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , 2018, 53, 1051-1054.	2.4	4
14	Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α -Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data. <i>Integrative Cancer Therapies</i> , 2018, 17, 1115-1124.	2.0	23
15	Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 27-35.	4.4	25
16	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. <i>Oncotarget</i> , 2018, 9, 23443-23450.	1.8	12
17	The predictive value of <i>Aspergillus</i> PCR testing on bronchoalveolar lavage fluid for early diagnosis of invasive pulmonary aspergillosis in hematologic patients. <i>Leukemia and Lymphoma</i> , 2017, 58, 2943-2946.	1.3	6
18	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e510-e523.	4.6	258

#	ARTICLE	IF	CITATIONS
19	Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study. Bone Marrow Transplantation, 2017, 52, 154-156.	2.4	27
20	Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant. Chemotherapy, 2017, 62, 58-61.	1.6	15
21	Chemoimmunotherapy with methotrexate, cytarabine, thiotepe, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematology, the, 2016, 3, e217-e227.	4.6	442
22	Follow-up of IgD- κ multiple myeloma by monitoring free light chains and total heavy chain IgD: A case report. Oncology Letters, 2016, 12, 1884-1888.	1.8	1
23	Flow cytometry characterization in central nervous system and pleural effusion multiple myeloma infiltration: an Italian national cancer institute experience. British Journal of Haematology, 2016, 172, 980-982.	2.5	11
24	Interference by biological anti-cancer drugs in electrophoretic and immunofixation techniques. Clinical Chemistry and Laboratory Medicine, 2016, 54, e297-9.	2.3	0
25	Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study. Journal of Experimental and Clinical Cancer Research, 2016, 35, 49.	8.6	4
26	Prospective surveillance vs clinically driven approach for CMV reactivation after autologous stem cell transplant. Journal of Infection, 2016, 72, 265-268.	3.3	17
27	Biosimilar filgrastim (Zarzio [®]) vs. lenograstim (Myelostim [®]) for peripheral blood stem cell mobilization in adult patients with lymphoma and myeloma: a single center experience. Leukemia and Lymphoma, 2016, 57, 489-492.	1.3	8
28	Hepatitis C and double-hit B cell lymphoma successfully treated by antiviral therapy. World Journal of Hepatology, 2016, 8, 1244.	2.0	6
29	Cytomegalovirus reactivation after autologous stem cell transplantation in myeloma and lymphoma patients: A single-center study. World Journal of Transplantation, 2015, 5, 129.	1.6	22
30	Comparison between biosimilar filgrastim vs other granulocyte colony stimulating factor formulations (originator filgrastim, pegfilgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network. British Journal of Haematology, 2015, 169, 293-296.	2.5	10
31	Differences among young adults, adults and elderly chronic myeloid leukemia patients. Annals of Oncology, 2015, 26, 185-192.	1.2	72
32	Cisplatin-induced inhibition of mTOR pathway enables stress-induced autophagy. EMBO Journal, 2015, 34, 1214-1230.	7.8	66
33	Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. Leukemia, 2015, 29, 689-695.	7.2	75
34	Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by 90Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma. Experimental Hematology and Oncology, 2015, 4, 17.	5.0	7
35	Relationship between circulating syndecan-1 levels (CD138s) and serum free light chains in monoclonal gammopathies. Journal of Experimental and Clinical Cancer Research, 2015, 34, 37.	8.6	5
36	Coexistence of three variants of cutaneous mastocytosis as the presenting sign of systemic mastocytosis with somatic c-kit D816V point mutation. International Journal of Dermatology, 2014, 53, 1265-1268.	1.0	1

#	ARTICLE	IF	CITATIONS
37	Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single institution study. <i>Transplant Infectious Disease</i> , 2014, 16, 1032-1038.	1.7	17
38	Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. <i>New England Journal of Medicine</i> , 2014, 371, 906-917.	27.0	697
39	Long-Term Response in a Patient with del(5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge. <i>Case Reports in Oncology</i> , 2014, 7, 277-284.	0.7	4
40	Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients. <i>British Journal of Haematology</i> , 2013, 160, 673-679.	2.5	23
41	Hepatitis C virus infection prevalence and liver dysfunction in a cohort of B-cell non-Hodgkin's lymphoma patients treated with immunochemotherapy. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 70-73.	1.5	29
42	IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012, 31, 17.	8.6	25
43	Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form. <i>Cancer</i> , 2012, 118, 5544-5549.	4.1	15
44	FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011, 30, 16.	8.6	6
45	Melphalan 200 mg/m ² versus melphalan 100 mg/m ² in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. <i>Blood</i> , 2010, 115, 1873-1879.	1.4	87
46	Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma. <i>Journal of Clinical Oncology</i> , 2010, 28, 2077-2084.	1.6	246
47	Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 35.	8.6	8
48	Follicular dendritic cell sarcoma of the neck: Report of a case treated by surgical excision and COP plus (PEG)-liposomal doxorubicin. <i>Journal of Experimental and Clinical Cancer Research</i> , 2008, 27, 33.	8.6	17
49	Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. <i>Blood</i> , 2008, 112, 3107-3114.	1.4	339
50	Arrest of Replication Fork Progression at Sites of Topoisomerase II-Mediated DNA Cleavage in Human Leukemia CEM Cells Incubated with VM-26. <i>Biochemistry</i> , 1997, 36, 5739-5748.	2.5	31
51	High-dose chemotherapy in adult acute myeloid leukemia: Rationale and results. <i>Leukemia Research</i> , 1996, 20, 535-549.	0.8	14